By a News Reporter-Staff News Editor at Biotech Week -- rEVO Biologics, an LFB company, announced that PM360, a premier monthly magazine for marketing decision-makers in the pharmaceutical, biotech, and medical device industries, recently named Robert Greif as a 2013 PM360 Trailblazer Award winner for Brand Champion of the Year for the Hematology/Oncology Category. In addition, he is one of four finalists in contention for the PM360 2013 Marketer of the Year Award (see also rEVO Biologics).
Robert Greif is Vice President of Commercial Operations for rEVO. He is leading the successful branding and market positioning of ATryn® Antithrombin (Recombinant), resulting in dramatic increases in brand sales.
Since 2009, the PM360 Trailblazer awards have recognized outstanding achievement and innovation in healthcare marketing. Each year, nominations are judged by the PM360 Editorial Advisory Board, a distinguished cross-section of industry experts. Trailblazer award winners are selected for their ability to stand out in the complex, ever-changing healthcare environment. In particular, judges looked for innovation, leadership, ability to communicate, and analytical and organizational skills.
The competition was fierce: out of more than 800 entrants, Robert Greif was one of the 14 Brand Champions selected. And, in addition to his Brand Champion Award, Robert is one of just four finalists being considered for 2013 Marketer of the Year, the ultimate prize among PM360 Awards.
"Robert's vision and leadership has not only helped drive ATryn sales, but also contributed to important changes in our corporate culture and increased visibility for rEVO," said Yann Echelard, Ph.D., President, rEVO Biologics. "We congratulate him on his Trailblazer Award and feel that his nomination for Marketer of the Year is testimony to our ability to compete in today's challenging marketplace."
The 2013 Marketer of the Year winner, along with the winners of all 2013 PM360 Awards, awards, will be announced on September 20th in New York City. The winners also will be featured in the October issue of PM360. PM360 is the premier source for information that product managers and pharma marketing professionals need to succeed in the complex, ever-changing healthcare environment. PM360 offers invaluable perspective on important industry issues through a full-circle combination of how-to information and thoughtful career insights. The PM360 Trailblazer Awards span five categories, including Company of the Year, Lifetime Achievement, Marketer of the Year, Brand Champion Awards, and Initiative Awards. About rEVO Biologics rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production-- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company's lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product. About LFB LFB Biotechnologies S.A. is a wholly-owned subsidiary of LFB S.A, a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, including Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 5th worldwide and is also among the leading European companies for the development of new-generation medicinal products based on biotechnologies. The LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. To that end, the LFB Group currently markets its products in 20 countries around the world with a global turnover of €466 millions in 2012.
Keywords for this news article include: Antithrombin (recombinant), Drugs, Serpins, Therapy, Angiology, Marketing, Advertising, rEVO Biologics, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC